Site icon Market Globalist

Kiromic BioPharma Inc. (KRBP) stock surges by in the after-hour trading session, given no current update.

ZOM Stock

ZOM Stock

Kiromic BioPharma Inc. (NASDAQ: KRBP) stock declined by 6.42% at the last close whereas the KRBP stock price rises by 5.71% in the after-hours trading session. Kiromic BioPharma is a preclinical stage pharmaceutical business focusing on finding, producing, and commercializing novel immuno-oncology applications through its extensive product pipeline, which is now in the pre-IND validation stages of the FDA clinical trial process.

>> 7 Top Picks for the Post-Pandemic Economy << 

KRBP stock’ Financial Highlights

Kiromic BioPharma has recently released its second-quarter 2021 financial results. Given below is the summary:

Read More

Dr. Maurizio Chiriva-Internati, PhD, CEO and President of Kiromic BioPharma stated,

During the first half of the year, Kiromic accomplished significant scientific and operational milestones, putting them in a good position to prepare their team and facilities for the first in-human dose in the first quarter of 2022. They filed two investigational new medication applications to the US Food and Drug Administration in May 2021 as a result of their work.

The strategy and objective is to create immunotherapies by enhancing target identification and validation in order to beat cancer. They believe that their treatments will be more successful than the existing variety of immunotherapies that use older targets considering the fact that they have newer targets.

Exit mobile version